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Introduction
In screened countries, the use of mammography and 
increased public awareness of breast cancer have resulted 
in women having smaller tumors and fewer involved nodes 
at presentation, reducing cases of locally advanced primary 
diagnosis, intended as “large operable cases” at stage IIB–
IIIA (T3N0–1) and “truly inoperable cases” (Figure 1), with 
involvement of supraclavicular or internal mammary nodal 
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involvement (T4N2–3)/inflammatory breast cancer (IBC) (1). 
Nevertheless, data emerging from National Cancer 
Database and the CONCORD high-resolution study 
reveal that approximately 8.5% of American and 4% of 
European patients still present with locally advanced breast 
cancer (LABC) (2); estimates that can reach up to 90% 
newly diagnosed breast cancers in low- to middle-income 
countries (3). 
In such worldwide delicate setting, current guidelines 
advise for neoadjuvant chemotherapy (NACT) as primary 
treatment (4). 
NACT achieves equivalent overall survival results, 
disease-free and distant disease recurrence that adjuvant 
systemic treatment (5-7) making the neoadjuvant approach 
a valid option, especially in breast cancer subtypes where 
the need for systemic therapy is clearly indicated, such 
as human epidermal growth factor receptor 2 (HER-2)-
positive and triple negative breast cancers (TNBC) (8,9). 
NACT rationale, is to offer effective systemic treatment 
while surgically down staging the cancer at presentation, 
potentially rendering operable patients who had been 
considered inoperable at the time of their diagnosis, as 
well as facilitating breast conserving surgery (BCS) when 
patients had initially needed mastectomy, with reported 
response rates ranging from 30% to 70% (10-15).
Besides the chance to pursue breast conservation, NACT 
also offers the potential advantage of gauging the sensitivity 
of the tumor to systemic therapy (16).
Moreover, pathological complete response to systemic 
therapy (no residual invasive disease in the breast and axilla 
regardless of the presence of residual in situ carcinoma) is 
a prognostic marker for long-term survival, especially in 
tumors with negative prognosis, such as TNBC disease 
(16,17-19).
Finally, in operable patients, NACT may offer the 
advantage over the adjuvant approach of anticipating 
Figure 1 Patient with locally advanced ductal carcinoma of the right breast determining a diffuse ulcerative and inflammatory clinical 
presentation. (A) Front view with diffuse peau d’orange and nipple areola complex ulceration; (B) left view; (C) magnetic resonance imaging, 
showing right breast 15-cm lesion, with skin involvement (arrows); (D) axillary lymph node involvement.
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administration of systemic treatment with a potential effect 
on systemic micrometastatic disease (16,18).
Despite these brilliant results of NACT (Figure 2), that 
can potentially lead to a significant decrease in mastectomy 
rates, several national surveys reported lower BCS than 
expected. 
In 2012, the European Society of Mastology (EUSOMA) 
reported the results from the EusomaDB survey (a 
prospective European database), which integrates data from 
European breast units located in Germany, Switzerland, 
Belgium, Austria, and Italy, reporting a mastectomy rate of 
25.1% (20). 
But a wide between-facilities variation was recently 
evidenced by a French survey, with mastectomy rates between 
15.0% and 45.7% (21).
In 2012, a United Kingdom retrospective study on 
hospital episode statistics (NHS records) showed that among 
breast cancer patients, 42.3% underwent mastectomy as a 
primary procedure (22).
In the USA, the multicenter Surveillance Epidemiology 
and End Results (SEER) study, which covered approximately 
28% of the U.S. population, confirmed in 2010 a decreasing 
trend in mastectomies (23) but subsequent reports revealed 
higher rates (24,25) and in 2015, a nationwide study on 
2.7 million patients, conducted by the American Cancer 
Society and the American College of Surgeons Commission 
on Cancer finally revealed a mastectomy rate of 35.5% (26). 
The lack of increased rates of BCS may be related to 
several difficulties:
Radiology related factors
After NACT, magnetic resonance imaging (MRI) has been 
proposed to have a role in guiding breast cancer surgery by 
measuring the size of residual tumor and has been shown to 
have highest sensitivity for detecting residual disease (27).
Currently, the role of MRI, despite having this highest 
correlation co-efficient to final pathology, may still 
underestimate and overestimate residual tumor size, leading 
to surgical over and under treatment. 
A recent metanalysis confirmed that both over- and 
under-estimation by MRI are possible, and observed limit 
of agreement (±3.8 cm) shows that errors within that range, 
that would be crucial for the choice of treatment are still 
possible and must be carefully avoided (28) by MRI skilled 
radiologists.
Surgeon related factors
Boughey et al. reported that in patients with T2 or T3 tumors, 
NACT lead to significantly less resected tissue than adjuvant 
chemotherapy, observing no change in rates of re-excision and 
thus leading to the conclusion that it is not necessary to excise 
the entire pre-chemotherapy volume of tissue (29).
Figure 2 Clinical complete response to neoadjuvant chemotherapy. (A) Patient presenting with a massive T4 ductal carcinoma of the 
left breast with skin infiltration; (B) magnetic resonance reconstructions, confirming a 9-cm left breast malignant neoplasm, infiltrating 
pectoralis fascia and overlying skin; (C) clinical complete response; (D) magnetic resonance reconstructions, that confirmed a clinical 
complete response to neoadjuvant treatment.
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Nevertheless, many breast surgeons routinely perform 
surgery based on pre-treatment characteristics rather than 
more appropriate post-treatment imaging and clinical 
results. This commits patients to suboptimal cosmetic 
results or mastectomy.
Patient related factors
In his systematic review, Hamelinck et al. reported that 46% 
of breast cancer patients prefer mastectomy versus BCS, in 
an attempt to reach better oncologic outcomes (30). 
This observation is a clear evidence that information 
between patient and clinicians is frequently lacking. 
Hospital related factors
Lack of training in breast conserving procedures, such as 
oncoplastic surgery (OS) was identified in several studies 
worldwide, determining a high variability among specialized 
breast centers and general hospitals (31-33). 
In Ontario, informal OS training opportunities exist; 
however, these are not well advertised or well known, 
leaving interested surgeons to seek out training in a 
piecemeal fashion (34). 
In the United States, only 53% of recent breast surgical 
oncology fellowship graduates were comfortable performing 
oncoplastic breast surgery (35).
In their national French survey, Clough and colleagues 
reported a strong variability in implementation of Level 
2 OS between surgeons (1.9–25.0%), with higher and 
significantly different rate of level 2 OS in dedicated cancer 
centers versus public practices (16.0% in dedicated cancer 
centers versus 7.6% in public hospitals) (21).
Factors related to lacking evidences in surgical breast 
conservation
Surgical management of breast cancer has undergone a 
continuous and dramatic evolution over the past 4 decades, 
trending away from radical procedures toward more breast-
conserving techniques, that provide patients with greater 
aesthetic satisfaction (36).
BCS followed by radiotherapy was confirmed by many 
randomized studies and meta-analyses as an alternative 
to mastectomy, reaching similar prognostic results while 
preserving the shape of the breast. 
The traditional approach to BCS consists of incision 
placement over the tumor, resection to clinically and/or 
radiographically clear margins, and closure of skin without 
parenchymal closure, thus leaving a seroma cavity (37-40).
While this may provide adequate cosmesis in the 
immediate postoperative period, over time the seroma 
absorbs, leaving a breast contour deformity, which is 
exacerbated by adjuvant radiotherapy (41). 
Factors known to contribute to poor cosmesis in BCS 
include high tumor volume to breast ratio, excision of >20% 
of breast volume, tumor location, breast ptosis, and large 
body habitus (42,43). 
Given these conditions, poor cosmesis is verified in up to 
40% of BCS patients and has been shown to significantly affect 
patients’ quality of life and psychosocial outcomes (44-47).
In an attempt to optimize the balance between oncologic 
results and cosmetic outcomes, new surgical procedures 
that combine the principles of surgical oncology and plastic 
surgery have been introduced in recent years. 
These new techniques called OS allow wider excisions 
with good oncologic outcomes, limiting the risk of a poor 
cosmesis (48-51) and further reducing mastectomy rates, 
thus improving patient’s quality of life and self-esteem 
(Figure 3) (52,53) .
Initial studies on OS focused primarily on cosmetic 
results. Only a few large-scale studies have evaluated 
survival, recurrence rates, and other measures of oncologic 
safety (54-59). 
As a consequence, OS was firstly established as a good 
compromise between larger excisions and good cosmetic 
results, but limited evidence hampered OS to become the 
oncologic leading solution for breast conserving treatment 
of breast cancer. 
Something started to change 3 years ago, when in 
2014, Losken and colleagues published a metanalysis that 
compared 24 OS papers (3,165 patients) versus 20 BCS 
papers (5,494 patients) reporting outcomes of both invasive 
and in situ breast cancer cases (60). 
Their analysis evidenced a larger average tumor size in 
the OS group [2.7 cm in OS group versus 1.2 cm in breast 
conservation therapy (BCT) group] with a significant reduction 
in positive margin rate defined according to the American 
Society of Clinical Oncology (ASCO) and the American Society 
for Radiation Oncology (ASTRO) guidelines, as tumor cells at 
the cut edge of the surgical specimen (12% in OS group versus 
21% in BCS group) (61,62).
With an average follow-up of 37.1 months (range, 
12.0–74.0 months) in the OS group, versus 64.4 months 
(range, 30.0–240.0 months) in BCS group, the authors 
confirmed that OS lead to a significant reduction in local 
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Figure 3 Oncoplastic inframammary fold approach of a lower outer right breast carcinoma. (A) Latero-lateral mammogram; (B) magnetic 
resonance reconstructions, confirming a 2.5-cm BIRADS4 right breast neoplasm; (C) preoperative assessment (front view); (D) preoperative 
assessment (lateral view); (E) outer external quadrantectomy with 20 % of glandular tissue excision; (F) surgical specimen; (E) postoperative 
cosmetic result (front view); (F) postoperative cosmetic result (lateral view).
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recurrence rate (4.2% after OS versus 7.0% after BCS); 
with an overall cosmetic satisfaction of 90% in the OS 
group versus 80% in BCS group.
Recently, in their 2016 systematic review, De La Cruz 
and colleagues included 55 articles, collectively evaluating 
results on 6,011 patients treated for early-stage invasive 
breast cancer, with a mean tumor size of 23 mm (39.3% of 
T2 cases) and mean follow-up of 50.5 months (63).
Their analysis confirmed that OS enables surgeons to 
successfully remove greater volumes of mammary gland 
with wider surgical margins (thereby reducing positive 
margin, re-excision and secondary mastectomy rates), with 
excellent/good cosmetic outcomes 86% of cases.
The authors reported no statistically significant difference 
in the incidence of postoperative seromas, hematomas, 
infection, nipple necrosis and wound dehiscence among 
women undergoing OS and BCS and, concerning oncologic 
safety, no significant differences in overall survival, disease-
free survival and local recurrence rate.
In patients with locally advanced breast cancer who 
received NACT, the evidences scenario is even more 
complex, as literature reporting the use of BCS and OS is 
limited and confounding.
Actually, reported results of breast conservation 
evidenced a discordance between recurrence rates of less 
than 10% (64,65) and studies that reported recurrence rates 
above 20% (66,67).
Recent evidences seem to refute initial data. In their 
2017 metanalysis, Zhou and colleagues reviewed 2000–2015 
literature selecting eight trials, with a total of 3,215 patients 
analyzed: 1,361 receiving BCS and 1,854 who underwent 
mastectomy (68). At 5 years follow-up, the prevalence of 
local recurrence was 9.2% in the BCS group, versus 8.3% in 
the mastectomy group and overall survival was significantly 
higher in the BCS group, confirming response to NACT a 
major prognostic factor.
Regarding the use of oncoplastic techniques in this 
setting, Mazouni et al. published in 2013 a case-control 
study of patients undergoing NACT, including 214 patients 
receiving BCS and 45 patients receiving OS (69).
At presentation, 25.8% were T3/T4 tumors and 
44.8% had metastatic lymph node disease. Patients were 
initially treated with anthracycline, cyclophosphamide and 
5-fluorouracil (5-FU) with or without docetaxel. Regarding 
surgery, the average excised tumor size was similar for 
both groups (40 mm) but the authors confirmed greater 
specimen volumes excised in patients undergoing OS. At a 
median follow-up of 46 months, local recurrence rate was 
5% in BCS group versus 4% in OS group. No differences 
were observed regarding distant recurrence or survival.
Recently, Vieira et al. performed a matching case-control 
study, evaluating results of 78 patients with LABC who 
underwent NACT (doxorubicin-cyclophosphamide regimen 
followed by paclitaxel regimen). After completion of neoadjuvant 
treatment, 26 patients received OS, whereas 52 BCS. The 
authors reported an average size tumor of 5.25 cm (88.5% larger 
than 3 cm). The clinical and pathological group characteristics 
were similar, except the weight of surgical specimens and 
surgical margins, which were higher in OS group. At 
67.1 months of follow-up, local recurrence was 11.5% in BCS 
group, versus 7.7% in OS group. The authors reported no 
difference in locoregional recurrence, overall survival and disease 
specific survival (70).
Conclusions
Recent literature demonstrates the benefits of OS, extending 
far beyond the mere reduction in poor cosmetic results, 
to the possibility of obtaining wider excisions with similar 
oncologic results observed in patients submitted to classic 
BCS and mastectomy. Future studies with longer follow-up 
and standardization of data are needed. Furthermore, what 
emerges from LABC literature is an imperative need of 
multidisciplinary breast centers worldwide diffusion, where 
breast-dedicated oncologists, radiologists and OS trained 
surgeons can offer patient-centered updated diagnostics, 
treatment protocols and surgical solutions, especially in a 
very delicate scenario, such as LABC treatment.
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